Cancer name Breast Cancer
Cancer Type BRCA
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment ado-trastuzumab emtansine
Drugstatus Approved
Drugbank ID DB05773
Checkpoints NA
Signature Type Protein
Signature RANTES
Official Symbol CCL5
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Our data also provide an explanation for the increased T cell and NKcell numbers owing to the increased amount of proinflammatory chemo-attractants such as MIG/CXCL9, MIP-1a/CCL3, MIP-1b/CCL4, and RANTES in tumors from mice treated with T-DM1 and the combination.
PMID 26606967
Title Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.